About

About BIOVECTRA BIOVECTRA (www.biovectra.com) is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for biologics, small molecules, bioreagents, lipids, pDNA, mRNA and LNP manufacturing, and fill/finish for drug products. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, over 630 employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada, we assure our programs advance on time and with the highest quality outcomes. About BIOVECTRA BIOVECTRA (www.biovectra.com) is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for biologics, small molecules, bioreagents, lipids, pDNA, mRNA and LNP manufacturing, and fill/finish for drug products. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, over 630 employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada, we assure our programs advance on time and with the highest quality outcomes. BIOVECTRA is a North American CDMO with over 50 years of experience specializing in clinical-to-commercial scale production of high-quality regulated active pharmaceutical ingredients (APIs) and intermediates. [[ Our Expertise ]] - Biologics – Large molecule therapeutics and bioprocessing solutions - Synthetic Small Molecules – Small-molecule API and intermediate manufacturing - Plasmid DNA (pDNA) & Messenger RNA (mRNA) – Nucleic acid development and production - Lipid Nanoparticle (LNP) Formulations – Drug delivery solutions for nucleic acid therapies - Highly Potent APIs (HPAPIs) – Safe and scalable production of complex compounds - Bioreagents – Custom enzyme and reagent manufacturing for diagnostics and research [[ Comprehensive Services ]] - Process Development & Scale-up – From early-stage research to commercial manufacturing - Analytical Development & Quality Control – Ensuring product integrity and compliance - Technology Transfer & cGMP Manufacturing – Seamless transition from lab to production - Clinical & Commercial Manufacturing – Supporting drug programs at all stages [[ Why BIOVECTRA? ]] - Trusted CDMO Partner – Decades of expertise in solving complex therapeutic challenges and a 2025 CDMO Leadership award winner in the Biologics category - State-of-the-Art Facilities – cGMP-compliant manufacturing sites in Prince Edward Island and Nova Scotia, Canada - Strong Team & Industry Commitment – Over 600 employees dedicated to innovation and quality In fall 2024, BIOVECTRA was acquired by Agilent Technologies, further strengthening our ability to support next-generation treatments and deliver greater value to our clients. Our mission remains the same: to develop and manufacture high-quality products that improve patients’ lives.